公开(公告)号：US10081623B2

公开(公告)日：2018-09-25

申请号：US15508122

申请日：2015-09-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jun Shi ,  William R. Ewing ,  Laura Nielsen ,  Zilun Hu ,  Mimi L. Quan

IPC: C07D401/06 ,  C07D403/06 ,  C07D403/12 ,  C07D409/12 ,  C07D401/12

CPC classification number: C07D409/12 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12

Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

公开(公告)号：US20170283403A1

公开(公告)日：2017-10-05

申请号：US15508122

申请日：2015-09-03

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Jun Shi ,  William R. Ewing ,  Laura Nielsen ,  Zilun HU ,  Mimi L. Quan

IPC: C07D409/12 ,  C07D401/06 ,  C07D403/06 ,  C07D403/12 ,  C07D401/12

CPC classification number: C07D409/12 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12

Abstract: The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.